Eligibility of sodium-glucose cotransporter-2 inhibitors in heart failure with preserved ejection fraction: Insights from the Colombian heart failure registry (RECOLFACA)

Background: The value of Sodium-glucose cotransporter-2 inhibitors (SGLT-2 inhibitor) therapy in individuals with heart failure with preserved EF (HFpEF) was unknown until the EMPEROR-Preserved trial. We aimed to assess the proportion of patients with HFpEF that are eligible for empagliflozin therap...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Juan Esteban Gómez-Mesa, Clara Saldarriaga, Alex Arnulfo Rivera-Toquica, Silfredo Arrieta-González, Alfonso Muñoz-Velásquez, Eduardo José Echeverry-Navarrete, Julián Rodrigo Lugo-Peña, Juan Alberto Cerón, Oscar Sveins Rincón-Peña, Luis Eduardo Silva-Diazgranados, Hugo Ernesto Osorio-Carmona, Alejandro Posada-Bastidas, Juan Camilo García, Alejandro David Ochoa-Morón, Luis Eduardo Echeverría
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2024-08-01
Edice:	International Journal of Cardiology: Heart & Vasculature
Témata:	Heart failure SGLT-2 inhibitor Ejection fraction Empagliflozin Colombia
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S2352906724001143
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!